

Inclusion and organizational information ENSURE trial

KWF IKZ2014-6677; NCT02413606

Title	ENdometrial cancer SURvivors' follow-up carE (ENSURE): Less is more? Randomized controlled trial to evaluate patient satisfaction and cost-effectiveness of a reduced follow-up schedule
Inclusion criteria	<ol style="list-style-type: none">1. Patients with endometrioid type endometrial carcinoma with stage 1 (FIGO, 2009) disease, with the following combination of stage, age and grade:<ul style="list-style-type: none">- Stage 1A, any age, grade 1 or 2;- Stage 1B, < 60 years, grade 1 or 2 without LVSI;2. Written informed consent;3. Sufficient oral and written command of the Dutch language.
Exclusion criteria	<ol style="list-style-type: none">1. Any other stage and type of endometrial carcinoma2. Histological types papillary serous carcinoma or clear cell carcinoma3. Uterine sarcoma (including carcinosarcoma)4. Radiotherapy for current endometrial carcinoma5. Previous malignancy (except for non-melanomatous skin cancer) < 5 yrs6. Having metastases of other tumours;7. Confirmed Lynch syndrome8. Previous pelvic radiotherapy
Intervention	4 follow-up visits, after 3, 12, 24 and 36 months (intervention) vs. regular follow-up according to the guideline, 10-13 visits during 5 years (control)
Coordinating and investigator	Dr. Nicole Ezendam, Netherlands Comprehensive Cancer Organisation (IKNL), Tilburg University, Eindhoven Tel.: 088 2346096; email: n.ezendam@iknl.nl
Datamanagement and randomisation	IKNL clinical research department Email: trialbureau@iknl.nl Tel.: 088 234 6500

Workflow

